APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
10 2023
Historique:
received: 12 07 2020
accepted: 17 08 2023
medline: 11 10 2023
pubmed: 22 9 2023
entrez: 21 9 2023
Statut: ppublish

Résumé

The single-stranded DNA cytosine-to-uracil deaminase APOBEC3B is an antiviral protein implicated in cancer. However, its substrates in cells are not fully delineated. Here APOBEC3B proteomics reveal interactions with a surprising number of R-loop factors. Biochemical experiments show APOBEC3B binding to R-loops in cells and in vitro. Genetic experiments demonstrate R-loop increases in cells lacking APOBEC3B and decreases in cells overexpressing APOBEC3B. Genome-wide analyses show major changes in the overall landscape of physiological and stimulus-induced R-loops with thousands of differentially altered regions, as well as binding of APOBEC3B to many of these sites. APOBEC3 mutagenesis impacts genes overexpressed in tumors and splice factor mutant tumors preferentially, and APOBEC3-attributed kataegis are enriched in RTCW motifs consistent with APOBEC3B deamination. Taken together with the fact that APOBEC3B binds single-stranded DNA and RNA and preferentially deaminates DNA, these results support a mechanism in which APOBEC3B regulates R-loops and contributes to R-loop mutagenesis in cancer.

Identifiants

pubmed: 37735199
doi: 10.1038/s41588-023-01504-w
pii: 10.1038/s41588-023-01504-w
pmc: PMC10562255
doi:

Substances chimiques

DNA, Single-Stranded 0
Cytidine Deaminase EC 3.5.4.5
Minor Histocompatibility Antigens 0
APOBEC3B protein, human EC 3.5.4.5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1721-1734

Subventions

Organisme : NIAID NIH HHS
ID : R37 AI064046
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA243306
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES030993
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009138
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA234228
Pays : United States
Organisme : Cancer Research UK
ID : CRUK DF-0119
Pays : United Kingdom
Organisme : NIEHS NIH HHS
ID : R01 ES032547
Pays : United States
Organisme : Howard Hughes Medical Institute
ID : 812337
Pays : United States
Organisme : Wellcome Trust
ID : 203141/Z/16/Z
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA198279
Pays : United States
Organisme : Wellcome Trust
ID : WT210641/Z/18/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : K99 AI147811
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA252081
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Green, A. M. & Weitzman, M. D. The spectrum of APOBEC3 activity: from anti-viral agents to anti-cancer opportunities. DNA Repair (Amst.) 83, 102700 (2019).
pubmed: 31563041
Harris, R. S. & Dudley, J. P. APOBECs and virus restriction. Virology 479–480, 131–145 (2015).
pubmed: 25818029
Kohli, R. M. et al. Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J. Biol. Chem. 285, 40956–40964 (2010).
pubmed: 20929867 pmcid: 3003395
Wang, M., Rada, C. & Neuberger, M. S. Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. J. Exp. Med. 207, 141–153 (2010).
pubmed: 20048284 pmcid: 2812546
Shi, K. et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat. Struct. Mol. Biol. 24, 131–139 (2017).
pubmed: 27991903
Petljak, M. & Maciejowski, J. Molecular origins of APOBEC-associated mutations in cancer. DNA Repair (Amst.) 94, 102905 (2020).
pubmed: 32818816
Casellas, R. et al. Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. Nat. Rev. Immunol. 16, 164–176 (2016).
pubmed: 26898111 pmcid: 4871114
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 pmcid: 7054213
Petljak, M. et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature 607, 799–807 (2022).
pubmed: 35859169 pmcid: 9329121
Carpenter, M. A. et al. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer. Preprint at bioRxiv https://doi.org/10.1101/2022.04.26.489523 (2023).
DeWeerd, R. A. et al. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers. Cell Rep. 38, 110555 (2022).
pubmed: 35320711 pmcid: 9283007
Seplyarskiy, V. B. et al. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. Genome Res. 26, 174–182 (2016).
pubmed: 26755635 pmcid: 4728370
Hoopes, J. I. et al. APOBEC3A and APOBEC3B preferentially deaminate the lagging strand template during DNA replication. Cell Rep. 14, 1273–1282 (2016).
pubmed: 26832400 pmcid: 4758883
Bhagwat, A. S. et al. Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in Escherichia coli. Proc. Natl Acad. Sci. USA 113, 2176–2181 (2016).
pubmed: 26839411 pmcid: 4776466
Haradhvala, N. J. et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538–549 (2016).
pubmed: 26806129 pmcid: 4753048
Morganella, S. et al. The topography of mutational processes in breast cancer genomes. Nat. Commun. 7, 11383 (2016).
pubmed: 27136393 pmcid: 5001788
Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).
pubmed: 27135926 pmcid: 4910866
Buisson, R. et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 364, eaaw2872 (2019).
pubmed: 31249028 pmcid: 6731024
Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
pubmed: 22608084 pmcid: 3414841
Taylor, B. J. et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2, e00534 (2013).
pubmed: 23599896 pmcid: 3628087
Bergstrom, E. N. et al. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature 602, 510–517 (2022).
pubmed: 35140399 pmcid: 8850194
Roberts, S. A. et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 46, 424–435 (2012).
pubmed: 22607975 pmcid: 3361558
Garcia-Muse, T. & Aguilera, A. R loops: from physiological to pathological roles. Cell 179, 604–618 (2019).
pubmed: 31607512
Petermann, E., Lan, L. & Zou, L. Sources, resolution and physiological relevance of R-loops and RNA-DNA hybrids. Nat. Rev. Mol. Cell Biol. 23, 521–540 (2022).
pubmed: 35459910
Brickner, J. R., Garzon, J. L. & Cimprich, K. A. Walking a tightrope: the complex balancing act of R-loops in genome stability. Mol. Cell 82, 2267–2297 (2022).
pubmed: 35508167 pmcid: 9233011
Serebrenik, A. A. et al. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proc. Natl Acad. Sci. USA 116, 22158–22163 (2019).
pubmed: 31611371 pmcid: 6825264
Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann. Oncol. 29, 563–572 (2018).
pubmed: 29324969 pmcid: 5888943
Roelofs, P. A., Martens, J. W. M., Harris, R. S. & Span, P. N. Clinical implications of APOBEC3-mediated mutagenesis in breast cancer. Clin. Cancer Res. 29, 1658–1669 (2023).
pubmed: 36478188
Cristini, A., Groh, M., Kristiansen, M. S. & Gromak, N. RNA/DNA hybrid interactome identifies DXH9 as a molecular player in transcriptional termination and R-loop-associated DNA damage. Cell Rep. 23, 1891–1905 (2018).
pubmed: 29742442 pmcid: 5976580
Leonard, B. et al. The PKC/NF-kappaB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res. 75, 4538–4547 (2015).
pubmed: 26420215 pmcid: 4631676
Tuduri, S. et al. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat. Cell Biol. 11, 1315–1324 (2009).
pubmed: 19838172 pmcid: 2912930
Smolka, J.A., Sanz, L.A., Hartono, S.R. & Chedin, F. Recognition of RNA by the S9.6 antibody creates pervasive artifacts when imaging RNA:DNA hybrids. J.Cell. Biol. 220, e202004079 (2021).
pubmed: 33830170 pmcid: 8040515
Kim, J. J. et al. Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity. Genes Dev. 33, 1751–1774 (2019).
pubmed: 31753913 pmcid: 6942044
Lee, S. Y., Kim, J. J. & Miller, K. M. Bromodomain proteins: protectors against endogenous DNA damage and facilitators of genome integrity. Exp. Mol. Med. 53, 1268–1277 (2021).
pubmed: 34548613 pmcid: 8492697
Ito, F., Fu, Y., Kao, S. A., Yang, H. & Chen, X. S. Family-wide comparative analysis of cytidine and methylcytidine deamination by eleven human APOBEC proteins. J. Mol. Biol. 429, 1787–1799 (2017).
pubmed: 28479091 pmcid: 5530319
Adolph, M. B., Love, R. P., Feng, Y. & Chelico, L. Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B. Nucleic Acids Res. 45, 11925–11940 (2017).
pubmed: 28981865 pmcid: 5714209
Chaurasiya, K. R. et al. Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein. Nat. Chem. 6, 28–33 (2014).
pubmed: 24345943
Wang, Y., Lu, J. J., He, L. & Yu, Q. Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS ONE 6, e23993 (2011).
pubmed: 21931633 pmcid: 3172214
Sanz, L. A. et al. Prevalent, dynamic, and conserved R-loop structures associate with specific epigenomic signatures in mammals. Mol. Cell 63, 167–178 (2016).
pubmed: 27373332 pmcid: 4955522
Manzo, S. G. et al. DNA topoisomerase I differentially modulates R-loops across the human genome. Genome Biol. 19, 100 (2018).
pubmed: 30060749 pmcid: 6066927
Nojima, T. et al. Deregulated expression of mammalian lncRNA through loss of SPT6 induces R-loop formation, replication stress, and cellular senescence. Mol. Cell 72, 970–984 (2018).
pubmed: 30449723 pmcid: 6309921
Kotsantis, P. et al. Increased global transcription activity as a mechanism of replication stress in cancer. Nat. Commun. 7, 13087 (2016).
pubmed: 27725641 pmcid: 5062618
Stork, C. T. et al. Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage. eLife 5, e17548 (2016).
pubmed: 27552054 pmcid: 5030092
Gorthi, A. et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 555, 387–391 (2018).
pubmed: 29513652 pmcid: 6318124
Holden, N. S. et al. Phorbol ester-stimulated NF-kappa B-dependent transcription: roles for isoforms of novel protein kinase C. Cell. Signal. 20, 1338–1348 (2008).
pubmed: 18436431
Xiao, X. et al. Structural determinants of APOBEC3B non-catalytic domain for molecular assembly and catalytic regulation. Nucleic Acids Res. 45, 7494–7506 (2017).
pubmed: 28575276 pmcid: 5499559
Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366–370 (2013).
pubmed: 23389445 pmcid: 3907282
Salamango, D. J. et al. APOBEC3B nuclear localization requires two distinct N-terminal domain surfaces. J. Mol. Biol. 430, 2695–2708 (2018).
pubmed: 29787764 pmcid: 6456046
Chan, K. et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067–1072 (2015).
pubmed: 26258849 pmcid: 4594173
Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).
pubmed: 23852170 pmcid: 3789062
Law, E.K. et al. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. J. Exp. Med. 217, e20200261 (2020).
pubmed: 32870257 pmcid: 7953736
Li, X. & Manley, J. L. Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122, 365–378 (2005).
pubmed: 16096057
Chen, L. et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol. Cell 69, 412–425 (2018).
pubmed: 29395063 pmcid: 5957072
Wan, Y. et al. Splicing function of mitotic regulators links R-loop-mediated DNA damage to tumor cell killing. J. Cell Biol. 209, 235–246 (2015).
pubmed: 25918225 pmcid: 4411280
ICGC/TCGAPan-Cancer Analysis of Whole Genomes Consortium Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Villarreal, O. D., Mersaoui, S.Y., Yu, Z., Masson, J.Y. & Richard, S. Genome-wide R-loop analysis defines unique roles for DDX5, XRN2, and PRMT5 in DNA/RNA hybrid resolution. Life Sci. Alliance 3, e202000762 (2020).
pubmed: 32747416 pmcid: 7409538
Rallapalli, K.L. & Komor, A.C. The design and application of DNA-editing enzymes as base editors. Annu. Rev. Biochem. 92, 43–79 (2023).
pubmed: 37018843
Chervova, A. et al. Analysis of gene expression and mutation data points on contribution of transcription to the mutagenesis by APOBEC enzymes. NAR Cancer 3, zcab025 (2021).
pubmed: 34316712 pmcid: 8253550
Chen, Y. et al. DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B. Emerg. Microbes Infect. 9, 366–377 (2020).
pubmed: 32056513 pmcid: 7033728
Kidd, J. M., Newman, T. L., Tuzun, E., Kaul, R. & Eichler, E. E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3, e63 (2007).
pubmed: 17447845 pmcid: 1853121
Land, A. M. et al. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J. Biol. Chem. 288, 17253–17260 (2013).
pubmed: 23640892 pmcid: 3682529
Lackey, L. et al. APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419, 301–314 (2012).
pubmed: 22446380 pmcid: 3368237
Lackey, L., Law, E. K., Brown, W. L. & Harris, R. S. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 12, 762–772 (2013).
pubmed: 23388464 pmcid: 3610724
Hultquist, J. F. et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220–11234 (2011).
pubmed: 21835787 pmcid: 3194973
McCann, J. L. et al. The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of cyclin D1. J. Biol. Chem. 294, 12099–12111 (2019).
pubmed: 31217276 pmcid: 6690700
Makharashvili, N. et al. Sae2/CtIP prevents R-loop accumulation in eukaryotic cells. eLife 7, e42733 (2018).
pubmed: 30523780 pmcid: 6296784
Mellacheruvu, D. et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat. Methods 10, 730–736 (2013).
pubmed: 23921808 pmcid: 3773500
Brown, W. L. et al. A rabbit monoclonal antibody against the antiviral and cancer genomic DNA mutating enzyme APOBEC3B. Antibodies (Basel) 8, 47 (2019).
pubmed: 31544853
Boguslawski, S. J. et al. Characterization of monoclonal antibody to DNA.RNA and its application to immunodetection of hybrids. J. Immunol. Methods 89, 123–130 (1986).
pubmed: 2422282
Phillips, D. D. et al. The sub-nanomolar binding of DNA-RNA hybrids by the single-chain Fv fragment of antibody S9.6. J. Mol. Recognit. 26, 376–381 (2013).
pubmed: 23784994 pmcid: 4061737
Sollier, J. et al. Transcription-coupled nucleotide excision repair factors promote R-loop-induced genome instability. Mol. Cell 56, 777–785 (2014).
pubmed: 25435140 pmcid: 4272638
Refsland, E. W. et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274–4284 (2010).
pubmed: 20308164 pmcid: 2910054
Cristini, A. et al. Dual processing of R-loops and topoisomerase I induces transcription-dependent DNA double-strand breaks. Cell Rep. 28, 3167–3181 (2019).
pubmed: 31533039 pmcid: 8274950
Beghe, C. & Gromak, N. R-loop immunoprecipitation: a method to detect R-Loop interacting factors. Methods Mol. Biol. 2528, 215–237 (2022).
pubmed: 35704194
Bhatia, V. et al. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature 511, 362–365 (2014).
pubmed: 24896180
Crossley, M.P. et al. Catalytically inactive, purified RNase H1: a specific and sensitive probe for RNA-DNA hybrid imaging. J.Cell. Biol. 220, e202101092 (2021).
pubmed: 34232287 pmcid: 8266564
Skourti-Stathaki, K., Kamieniarz-Gdula, K. & Proudfoot, N. J. R-loops induce repressive chromatin marks over mammalian gene terminators. Nature 516, 436–439 (2014).
pubmed: 25296254 pmcid: 4272244
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
pubmed: 20110278 pmcid: 2832824
Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
pubmed: 27079975 pmcid: 4987876
Zhang, Y. et al. Model-based analysis of ChIP–seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).
pubmed: 28263959 pmcid: 5600148
Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Seiler, M. et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282–296 (2018).
pubmed: 29617667 pmcid: 5933844
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
pubmed: 26899170 pmcid: 4762164
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592 pmcid: 3776390
Eisenberg, E. & Levanon, E. Y. Human housekeeping genes, revisited. Trends Genet. 29, 569–574 (2013).
pubmed: 23810203
Bergstrom, E. N., Kundu, M., Tbeileh, N. & Alexandrov, L. B. Examining clustered somatic mutations with SigProfilerClusters. Bioinformatics 38, 3470–3473 (2022).
pubmed: 35595234 pmcid: 9237733
Bergstrom, E. N., Barnes, M., Martincorena, I. & Alexandrov, L. B. Generating realistic null hypothesis of cancer mutational landscapes using SigProfilerSimulator. BMC Bioinformatics 21, 438 (2020).
pubmed: 33028213 pmcid: 7539472

Auteurs

Jennifer L McCann (JL)

Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.

Agnese Cristini (A)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Emily K Law (EK)

Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.

Seo Yun Lee (SY)

Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Department of Life Science and Multidisciplinary Genome Institute, Hallym University, Chuncheon, Republic of Korea.

Michael Tellier (M)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Department of Molecular and Cell Biology, University of Leicester, Leicester, UK.

Michael A Carpenter (MA)

Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Biochemistry and Structural Biology Department, University of Texas Health San Antonio, San Antonio, TX, USA.
Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA.

Chiara Beghè (C)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Jae Jin Kim (JJ)

Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Department of Life Science and Multidisciplinary Genome Institute, Hallym University, Chuncheon, Republic of Korea.

Anthony Sanchez (A)

Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.

Matthew C Jarvis (MC)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.

Bojana Stefanovska (B)

Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Biochemistry and Structural Biology Department, University of Texas Health San Antonio, San Antonio, TX, USA.
Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA.

Nuri A Temiz (NA)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA.

Erik N Bergstrom (EN)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
Department of Bioengineering, UC San Diego, La Jolla, CA, USA.
Moores Cancer Center, UC San Diego, La Jolla, CA, USA.

Daniel J Salamango (DJ)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.

Margaret R Brown (MR)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.

Shona Murphy (S)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Ludmil B Alexandrov (LB)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
Department of Bioengineering, UC San Diego, La Jolla, CA, USA.
Moores Cancer Center, UC San Diego, La Jolla, CA, USA.

Kyle M Miller (KM)

Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA. kyle.miller@austin.utexas.edu.
Livestrong Cancer Institutes, Dell Medical School, University of Texas at Austin, Austin, TX, USA. kyle.miller@austin.utexas.edu.

Natalia Gromak (N)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK. natalia.gromak@path.ox.ac.uk.

Reuben S Harris (RS)

Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA. rsh@uthscsa.edu.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. rsh@uthscsa.edu.
Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA. rsh@uthscsa.edu.
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA. rsh@uthscsa.edu.
Biochemistry and Structural Biology Department, University of Texas Health San Antonio, San Antonio, TX, USA. rsh@uthscsa.edu.
Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA. rsh@uthscsa.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH